JCI - Iron supplementation alleviates pathologies in a mouse model of facioscapulohumeral muscular dystrophy

Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy)...

Muscle imaging in facioscapulohumeral muscular dystrophy research: A scoping review and expert recommendations

https://pmc.ncbi.nlm.nih.gov/articles/PMC11817091/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11708601/

DUX4-induced HSATII RNA accumulation drives protein aggregation impacting RNA processing pathways

Analysis of Body Fluid Distribution, Phase Angle and Its Association With Maximal Oxygen Consumption in Facioscapulohumeral Dystrophy: An Observational Study

SMCHD1 genetic variants in type 2 facioscapulohumeral dystrophy and challenges in predicting pathogenicity and disease penetrance - European Journal of Human Genetics

SOLVE FSHD Challenges Innovators with USD$10 Million Bonus Prize to Accelerate FSHD Breakthroughs in XPRIZE Healthspan Competition

Muscle Proteome Analysis of Facioscapulohumeral Dystrophy Patients Reveals a Metabolic Rewiring Promoting Oxidative/Reductive Stress Contributing to the Loss of Muscle Function

Management of FSHD symptoms: current assistive technologies and pharmacological approaches

https://www.genengnews.com/topics/drug-discovery/novartis-buys-kate-therapeutics-expanding-in-neuro-gene-therapy/

https://www.sciencedirect.com/science/article/pii/S0960896624005388

https://www.nmd-journal.com/article/S0960-8966(24)00537-6/fulltext

Molecular, Histological, and Functional Changes in Acta1-MCM;FLExDUX4/+ Mice

629P Co-producing UK care quality standards in facioscapulohumeral muscular dystrophy (FSHD) in partnership with people with FSHD, carers and healthcare professionals: a qualitative focus group study

628P Development of a CRISPR/CasX 4q telomeric region ablation strategy for FSHD1 using an isogenic hiPSC line and a FSHD1 fibroblast cell line